Radio Astronomy

Contains reports on three research project.National Science Foundation (Grant GP-21348A#2)California Institute of Technology (Contract 952568)National Aeronautics and Space Administration (Grant NGR 22-009-421)U. S. Air Force - Electronic Systems Division (Contract F19628-73-C-0196

Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: Subgroup analysis of the DISTINCT randomised trial

The DISTINCT study (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) investigated the efficacy and safety of nifedipine GITS/candesartan cilexetil combinations vs respective monotherapies and placebo in patients with hypertension. This descriptive sub-analysis examined blood pressure (BP)-lowering effects in high-risk participants, including those with renal impairment (estimated glomerular filtration rate<90 ml min-1, n=422), type 2 diabetes mellitus (n=202), hypercholesterolaemia (n=206) and cardiovascular (CV) risk factors (n=971), as well as the impact of gender, age and body mass index (BMI). Participants with grade I/II hypertension were randomised to treatment with nifedipine GITS (N) 20, 30, 60 mg and/or candesartan cilexetil (C) 4, 8, 16, 32 mg or placebo for 8 weeks. Mean systolic BP and diastolic BP reductions after treatment in high-risk participants were greater, overall, with N/C combinations vs respective monotherapies or placebo, with indicators of a dose-response effect. Highest rates of BP control (ESH/ESC 2013 guideline criteria) were also achieved with highest doses of N/C combinations in each high-risk subgroup. The benefits of combination therapy vs monotherapy were additionally observed in patient subgroups categorised by gender, age or BMI. All high-risk participants reported fewer vasodilatory adverse events in the pooled N/C combination therapy than the N monotherapy group. In conclusion, consistent with the DISTINCT main study outcomes, high-risk participants showed greater reductions in BP and higher control rates with N/C combinations compared with respective monotherapies and lesser vasodilatory side-effects compared with N monotherapy

Continuations from Generalized Stack Inspection

Implementing first-class continuations can pose a challenge if the target machine makes no provisions for accessing and re-installing the run-time stack. In this paper, we present a novel translation that overcomes this problem. In the first half of the paper, we introduce a theoretical model that shows how to eliminate the capture and the use of first-class continuations in the presence of a generalized stack inspection mechanism. The second half of the paper explains how to translate this model into practice in two different contexts. First, we reformulate the servlet interaction language in the PLT Web server, which heavily relies on first-class continuations. Using our technique, servlet programs can be run directly under the control of non-cooperative web servers such as Apache. Second, we show how to use our new technique to copy and reconstitute the stack on MSIL. Net using exception handlers. This establishes that Scheme’s first-class continuations can exist on non-cooperative virtual machine